Nucleosides and nucleotides play important roles in cell physiology both as nutrients and modulators of cellular homeostasis. They are implicated in crucial processes such as DNA and RNA synthesis, cell signaling, and metabolic regulation. Moreover, nucleoside and nucleobase analogs are currently used in the treatment of solid tumors, lymphoproliferative diseases, viral infections such as hepatitis and AIDS, and some inflammatory diseases such as Crohn ([@B94]; [@B65]). Nucleosides and nucleoside-derived drugs are hydrophilic molecules and diffuse, if they can, slowly across cell membranes. Thus, to exert their physiological and cytotoxic effects, specific membrane transporters that mediate their flux across cell membranes are required. Nucleoside transporters (NTs) are integral membrane proteins implicated in the salvage of natural nucleobases and nucleosides for nucleic acid synthesis. NTs belong to solute carrier families 28 and 29 (SLC28 and SLC29), which encode human concentrative nucleoside transporters (hCNT) and equilibrative nucleoside transporter proteins (hENTs), respectively ([@B101]; [@B121]; [@B15]; [@B104]). However, the chemical modifications of the nucleoside analogs can alter their ability to interact with canonical transporter proteins implicated in the uptake of natural nucleosides. The paradigm of this concept is the lack of interaction of hCNT1 with those antiviral drugs lacking the 3^′^OH of the ribose, which appears to be an essential structural requirement for substrate translocation ([@B14]). In fact, the structural requirements for nucleoside-NT interactions have already been reviewed elsewhere ([@B15]). Therefore, in some cases additional carrier proteins become major players in drug bioavailability, and likely, drug action. In this sense, members of the SLC22 gene family, which encode human organic cation transporters, (hOCTs) and organic anion transporters (hOATs) are also implicated in the uptake of nucleoside-derived drugs ([@B94]). Moreover, although both hENT1 and hENT2 have been reported to translocate some nucleobases ([@B160]), other transporter proteins might contribute to the uptake of purine and pyrimidine nucleobases into cells despite the molecular entity behind them still have to be identified ([@B155]; [@B129]).

NUCLEOSIDE-DERIVED DRUG TRANSPORTERS
====================================

SLC28
-----

The three human CNT proteins (hCNTs) mediate the unidirectional flow of nucleosides in an energy-costly process coupled to the influx of sodium ions. All three members of the SLC28 gene family accept uridine as substrate, but differ in their selectivity for other substrates. Thus, hCNT1 prefers pyrimidine nucleosides, hCNT2 purine nucleosides and uridine, and hCNT3 transports both pyrimidine and purine nucleosides. Importantly, they all have the ability of translocating selected nucleoside-derivatives currently used in anticancer and antiviral therapies, being major determinants of drug action ([@B63]; [@B34]). The sodium/nucleoside coupling ratio of hCNT1 and hCNT2 is 1:1, while hCNT3 shows a 2:1 stoichiometry ([@B140], [@B141]). Interestingly, hCNT3 is the only transporter in this family able to accept protons as driving force ([@B142]; [@B51]). Based upon its broad selectivity and highly potential concentrative activity, hCNT3 is considered to be a major player in nucleoside-derived drug uptake.

hCNT proteins, initially thought to be expressed almost exclusively in polarized epithelia, are in fact broadly expressed but not ubiquitous. In most polarized epithelia, these proteins localize at the apical membrane, thus facilitating vectorial flux of nucleosides across the barriers ([@B84], [@B85]; [@B79]; [@B35]). In fact, CNTs are expressed in all tissues which are considered to be relevant for drug pharmacokinetics (i.e., intestine, kidney, liver, and blood brain barrier).

SLC29
-----

The human ENT proteins (hENTs) family contain four members, hENT1-4 ([@B101]; [@B121]; [@B15]; [@B104]). hENTs, except hENT4, mediate the facilitative transport of natural nucleosides with broad selectivity but relatively lower affinity than their CNT-type counterparts ([@B5]; [@B162]). In fact, hENT1-3 proteins transport both purine and pyrimidine nucleosides, despite significant differences in substrate selectivity. The two best-characterized transporters hENT1 and hENT2 can be distinguished on the basis of their sensitivity to inhibition by the nucleoside analog NBTI, with hENT1 being much more sensitive than hENT2. Both transporters are also inhibited by vasodilation potentiators including dipyridamole and dilazep, being hENT1 also more sensitive than hENT2 ([@B153]). Additionally, hENT2 transports nucleobases ([@B118]). Moreover, hENT1 has recently been shown to transport some nucleobases, albeit with low kinetic efficiencies compared to hENT2 ([@B160]). hENT3 can also transport the nucleobase adenine and is not sensitive to inhibition by NBTI. This transporter protein was initially reported to be localized in lysosomes and, more recently, identified in mitochondria ([@B53]). hENT3 is the only NT studied to date that has been associated with inherited human diseases. Several syndromes, including the H syndrome ([@B98], [@B99]; [@B10]; [@B62]) and the pigmented hypertrichosis with insulin dependent diabetes (PHID) syndrome ([@B143]) have been associated with mutations in the SLC29A3 gene. Finally, hENT4 may not be considered a "canonical" NT because it mostly transports organic cations, although it is a suitable adenosine transporter under acidic pH conditions ([@B8]).

hENT1 and hENT2 are ubiquitously distributed, but differ in abundance among tissues and cell types ([@B5]). These transporters seem to be mainly, but not exclusively, localized at the basolateral side of polarized epithelial cells ([@B79]; [@B85]), contributing to the vectorial flux of nucleosides across these barriers.

SLC22
-----

The organic ion transporter family, SLC22, includes 22 transporters. Within the family, there are several subfamilies, which consist of members that cluster together based on sequence homology, including the OATs, the OCTs, and the OCTNs.

hOCT1, hOCT2, and hOCT3 are encoded by genes SLC22A1-3 ([@B74]; [@B55]; [@B56]). Transport of organic cations by hOCTs is electrogenic, sodium-independent, and bidirectional across the plasma membrane. The driving force is supplied by the electrochemical gradient of the transported organic cation. These proteins display broad substrate selectivity, transport positively charged compounds with a relative molecular mass below 500 and target both endogenous (hormones, neurotransmitters, creatinine, and others) and exogenous molecules (antiviral, antidiabetic, antiemetic, cytostatic among other drugs). hOCTs exhibit broad tissue distribution and are expressed in epithelial cells and neurons ([@B76]; [@B108]), whereas its occurrence in immune system cells has also been reported ([@B95]).

hOAT1, hOAT2, hOAT3, and hOAT4 are encoded by genes SLC22A6-8 and 11 ([@B134]; [@B152]). hOATs exchange extracellular against intracellular divalent organic anions. The concentration of the intracellular organic anion must be higher in the cytosol than outside the cell in order to drive the uptake of organic anions through OATs. This concentration difference is maintained by sodium-coupled anion transporters located at the same membrane as the respective OATs. These proteins accept a huge variety of chemically unrelated endogenous and exogenous organic anions including many drugs ([@B75]). OATs play a pivotal role in renal excretion of water-soluble, negatively charged organic compounds including endogenous waste products, numerous drugs, and drug metabolites. OATs are located at the plasma membrane of epithelial cells of proximal tubules, the site of efficient renal organic anion secretion. Selected OATs are present also outside the kidneys, e.g., in liver, placenta, nasal epithelium, and brain, where they serve special functions ([@B152]; [@B12]; [@B75]).

Although the SLC22 family include other members, those are the ones that are most likely to transport nucleoside analogs ([@B34]; [@B94]; [@B75]).

NUCLEOSIDE ANALOGS IN MEDICINAL CHEMISTRY
=========================================

NUCLEOSIDE ANALOGS IN CANCER TREATMENT
--------------------------------------

Nucleoside analogs were among the first chemotherapeutic agents used in the treatment of malignant diseases and today their activity is well established, showing a broad clinical use. The research on purines and purine analogs was recognized with the Nobel Prize in Physiology or Medicine in 1988. In the early 50' Gertrude Elion and George Hitchings developed thioguanine and 6-mercaptopurine (6-MP) against leukemia. Later, they also developed, azathioprine, a drug that prevents rejection of transplanted organs and allopurinol which is used in the treatment of gout. Essentially, their research involved the rational development of a series of new drugs based upon the understanding of basic biochemical and physiological processes ([@B30]). (<http://www.nobelprize.org/nobel_prizes/medicine/laureates/1988/press.html>).

The anticancer nucleosides include analogs of pyrimidine and purine nucleosides (**Table [1](#T1){ref-type="table"}**). The basic mechanism of action of most nucleoside analogs used in cancer treatment is similar ([@B120]). They get into cells where they are converted to analogs of cellular nucleotides (often the real active drugs) by enzymes of either the purine or the pyrimidine metabolic pathways. Nucleotide drugs can then be incorporated into nucleic acids and, in most cases, inhibit enzymes implicated in DNA synthesis, causing DNA damage and induction of apoptosis. Selective differences among them can also be found and they often rely upon their ability to interact with enzymes of the purine and pyrimidine salvage pathways.

###### 

Nucleoside analogs used for cancer treatment.

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Drug name                  Therapeutic use                Analogous to   FDA approval   Identified uptake transporter       Reference
  -------------------------- ------------------------------ -------------- -------------- ----------------------------------- -------------------------
  Mercaptopurine             Lymphoproliferative diseases   Purine         1953           hCNT3, hENT1, hENT2                 [@B41], [@B160]

  Cytarabine                 Lymphoproliferative diseases   Pyrimidine     1969           hCNT1, hENT1, hENT2                 [@B140]; [@B19]

  Fludarabine                Lymphoproliferative diseases   Purine         1991           hCNT2, hCNT3, hENT1, hENT2          [@B71]

  Pentostatin                Lymphoproliferative diseases   Purine         1991           hENT1, hENT2                        [@B156]

  Cladribine                 Lymphoproliferative diseases   Purine         1993           hCNT2, hCNT3, hENT1, hENT2          [@B71]

  Azacitidine                Lymphoproliferative diseases   Pyrimidine     2004           hCNT1, hCNT2, hCNT3, hENT1,\        [@B133], [@B23]
                                                                                          hENT2, hENT3, hENT4                 

  Clofarabine                Lymphoproliferative diseases   Purine         2004           hCNT2, hCNT3, hENT1, hENT2          [@B71]

  Nelarabine (AraG)^1^       Lymphoproliferative diseases   Purine         2005                                               

  Decitabine                 Lymphoproliferative diseases   Pyrimidine     2006           hENT1, hENT2                        [@B23], [@B1]

  Floxuridine                Solid tumors                   Pyrimidine     1970           hCNT1, hCNT2, hCNT3                 [@B81], [@B140], [@B61]

  Gemcitabine                Solid tumors                   Pyrimidine     1996           hCNT1, hCNT3, hENT1, hENT2, hENT3   [@B83], [@B61], [@B53]

  Capecitabine (5-DFUR)^2^   Solid tumors                   Pyrimidine     1998                                               

  5-Fluorouracil             Solid tumors                   Pyrimidine     1998           hENT1, hENT2, hOAT2                 [@B73], [@B160]
  -----------------------------------------------------------------------------------------------------------------------------------------------------

1

Nelarabine is a prodrug of AraG, which is translocated by hENT1 and hENT2 (

Prus et al., 1990

).

2

Capecitabine is a prodrug of 5-DFUR, which is translocated by hCNT1, hCNT2, hCNT3, hENT1 and hENT2 (

Lang et al., 2001

;

Mata et al., 2001

;

Molina-Arcas et al., 2006

;

Errasti-Murugarren et al., 2007

). In gray, transporters for which weak substrate interaction has been reported.

In general, purine nucleosides work almost exclusively against hematological malignancies, while pyrimidine analogs typically show efficacy against both blood cancers and solid tumors. NTs display different affinities for the analogs and their substrate selectivity has been comprehensively reviewed elsewhere. Thus, the tissue distribution of the transporters has a large impact on their therapeutic effect. As expected, purine-based nucleoside analogs such as fludarabine, cladribine, and clofarabine are substrates for hENT1, hENT2, hCNT3, and hCNT2 ([@B81]; [@B102]; [@B71]; [@B119]; [@B34]). Conversely, pyrimidine analogs such as gemcitabine, cytarabine, and azacytidine are transported by hCNT1 in addition to hENT1, hENT2, and hCNT3 ([@B83]; [@B140]; [@B19]; [@B31]; [@B35]; [@B34]; [@B1]). Nucleobases, such as 5-fluorouracil and 6-MP have also been reported to interact with hENT1 and hENT2 proteins, although their affinity constants are within the mM range ([@B160]).

NUCLEOSIDE ANALOGS IN VIRAL DISEASES
------------------------------------

During the past two decades, antiviral drugs have become crucial in the management of several viral infections, including HSV, HIV, HBV, HCV, and CMV infections. Prominent among these drugs are nucleoside derivatives(**Table [2](#T2){ref-type="table"}**), which can act as potent antiviral agents owing to their ability to inhibit viral DNA polymerases and reverse transcriptases, which have key roles in the various viral life cycles. Antiviral nucleoside and nucleotide analogs are structurally more diverse than anticancer nucleoside analogs, as they consist of nucleosides, nucleotides, and acyclic nucleosides ([@B24]). Acyclic nucleosides have been approved for the treatment of various DNA virus infections (cidofovir), hepatitis B (adefovir), and AIDS (tenofovir).

###### 

Nucleoside analogs used as antiviral agents.

  Drug name                                  Therapeutic use    Analogous to   FDA approval   Identified uptake transporter                            Reference
  ------------------------------------------ ------------------ -------------- -------------- -------------------------------------------------------- ----------------------------------------------------------
  Ribavirin                                  HCV                Purine         1998           hCNT2, hCNT3, hENT1, hENT2                               [@B64], [@B122], [@B61], [@B52], [@B45]
  Sofosbuvir                                 HCV                Purine         2013           hOATP1B1                                                 [@B46]
  Adefovir                                   HBV                Purine         2003           hOAT1, hOAT3                                             [@B18], [@B17]), [@B150]
  Entecavir                                  HBV                Purine         2004           hOAT1, hOAT3, hPEPT2                                     [@B158], [@B159])
  Telbivudine                                HBV                Pyrimidine     2006                                                                    
  Lamivudine                                 HIV, HBV           Pyrimidine     1995           hENT3, hOCT1, hOCT2, hOCT3                               [@B66], [@B53], [@B96]
  Tenofovir                                  HIV, HBV           Purine         2001           hOAT1, hOAT3                                             [@B17], [@B150]
  Emtricitabine                              HIV, HBV           Pyrimidine     2003           hOCT1, hOCT2, hOCT3                                      [@B96]
  Zidovudine                                 HIV                Pyrimidine     1987           hCNT1, hCNT3, hENT2, hENT3, hOAT1, hOAT2, hOAT3, hOAT4   [@B161], [@B147], [@B14], [@B140], [@B6], [@B61], [@B96]
  Didanosine                                 HIV                Purine         1991           hCNT2, hCNT3, hENT1, hENT2, hENT3                        [@B132], [@B131]), [@B161], [@B6], [@B61]
  Zalcitabine                                HIV                Pyrimidine     1992           hCNT3, hENT1, hENT2, hOCT1, hOCT2                        [@B131], [@B161], [@B6], [@B66]
  Stavudine                                  HIV                Pyrimidine     1994           hCNT1, hCNT3, hENT3                                      [@B14], [@B61], [@B53]
  Abacavir                                   HIV                Purine         1998           hOCT1, hOCT2, hOCT3                                      [@B96]
  Acyclovir                                  Herpes             Purine         1982           hOCT1, hOAT1, hOAT2                                      [@B147], [@B16]
  Penciclovir                                Herpes             Purine         2002           hOAT1, hOAT2, hOAT3                                      [@B16]
  Famciclovir (Penciclovir)^1^               Herpes             Purine         2007                                                                    
  Ganciclovir                                Herpes, CMV        Purine         1989           hOCT1, hOAT1, hOAT2                                      [@B147], [@B16]
  Valaciclovir (Acyclovir valyl ester)       Herpes, CMV, EBV   Purine         1996           hPEPT1, hPEPT2, ATB(0,+)                                 [@B47], [@B59]
  Cidofovir                                  CMV                Pyrimidine     1996           hOAT1, hOAT3                                             [@B18], [@B150]
  Valganciclovir (Ganciclovir valyl ester)   CMV                Purine         2001           hPEPT1, hPEPT2, ATB(0,+)                                 [@B145], [@B149]

1

Famciclovir is a prodrug of Penciclovir.

In gray, transporters where only interaction has been demonstrated.

Some NT proteins and particularly, but not exclusively, the broad selective transporter hCNT3 can interact and translocate different types of antiviral drugs, such as ribavirin and zidovudine, among others ([@B61]; [@B35]). However, hOCT proteins also appear to interact with these drugs with high affinity, lamivudine being a substrate and tenofovir, abacabir, and zidovudine high affinity inhibitors of hOCT1, hOCT2, and hOCT3 ([@B96]). This might be particularly relevant in the clinics, because AIDS patients are under combined therapy and hOCT1 and hOCT3 are highly expressed in target cells (i.e., CD4^+^ T cells; [@B95]). Moreover, hOCTs (particularly hOCT1) are highly polymorphic proteins, with some variants showing high allelic frequency and already shown to be relevant in the pharmacokinetics of other drugs such as metformin ([@B34]). Other SLC22 members might also interact with nucleoside-derived drugs ([@B34]; [@B15]), whereas for novel drugs at the pre-clinical stages, or even in the clinics such as the pronucleotide sofosbuvir, the best candidates to mediate their cellular uptake still have to be identified.

NUCLEOSIDE ANALOGS IN INFLAMMATORY DISEASES
-------------------------------------------

The thiopurines, 6-MP, and its pro-drug azathioprine (AZA) have been a cornerstone of medical management of patients with inflammatory bowel disease (IBD) and many rheumatoid disorders.

Thiopurines are metabolized to their end products, 6-methymercaptopurine (6-MMP) and the 6-thioguanine nucleotides (6-TGN). Although these nucleotides disturb proper DNA synthesis it has not been conclusively shown, that 6-TGN are the only molecules responsible for proper action. However, immunosuppressive function seems to be mediated in part by induction of apoptosis in lymphocytes. A correlation of therapeutic benefit and 6-TGN levels has been put into question. Although thiopurines are widely used, several safety concerns remain regarding the optimal treatment regimens. Thioguanine has been proposed as an alternative to overcome such problems, as it skips the metabolic conversion to 6-MMP which is responsible for hepatotoxicity ([@B7]; [@B42]; [@B43]).

TRANSPORTERS AS BIOMARKERS
==========================

Transporter function may be influenced by multiple factors and is likely to be highly variable among individuals ([@B113]; [@B136]; [@B127]). Thus, interindividual heterogeneity in response to therapy can be somehow related to inherent transporter function variability among patients and also to altered transporter expression in target cells, even as a result of the disease itself. In this context, transportome profiles and their associated pharmacogenetics might prove suitable for the prediction of treatment outcomes, and ideally should be helpful in decision making processes, such as choice of treatment (drug and dose) and in anticipating drug--drug interactions when patients face drug combination schedules. In fact, drug transporters can often be inhibited by numerous compounds, either other drugs or endogenous substrates, typically by competition for recognition and binding. These interactions may even result in altered drug pharmacokinetics. Genetic heterogeneity of the transporter-encoding genes may also determine variable transporter function, either by increasing or by reducing the individual overall exposure to a substrate, also depending upon the tissue expression and localization of particular transporters.

In summary, inter-individual differences in transporter expression and function and, perhaps more importantly, altered expression either due to the oncogenic process itself, to viral infection or to inflammation might modulate the transporter profile of target cells, thereby determining drug bioavailability and action.

BIOMARKERS OF DRUG SUSCEPTIBILITY
---------------------------------

As mentioned above, NT proteins are necessary for nucleoside analogs to enter into cells and exert their pharmacological action. The analysis of the role played by NTs in drug sensitivity and clinical outcomes of cancer patients initially focused on lymphoproliferative diseases.

Leukemic cells express both CNTs and hENTs and the analysis of these proteins in cells from 22 patients with primary CLL cells similarly expressed hENT1, hENT2, hCNT2, and hCNT3 mRNAs. However, fludarabine accumulation in CLL cells is mainly mediated by hENT1 and hENT2 ([@B100]). Moreover, fludarabine transport correlates with hENT2 protein expression and activity, whereas in Mantle Cell Lymphoma (MCL) hENT1 correlates with *ex vivo* gemcitabine sensitivity ([@B86]).

Furthermore, data suggest that hENT1 expression influences response to cytarabine, but not sufficient to support its use as a biomarker for guiding treatment in Acute Myeloid Leukemia (AML). In any case, permeant nucleoside analogs have been designed as a way to bypass NT function. Thus the activity of elacytarabine (the elaidic acid ester derivative of cytarabine) is not significantly predicted by the hENT1 expression level ([@B135]).

To date, most studies in solid tumors focused on hENT1 levels and clinical response to gemcitabine, mainly in pancreatic cancer (**Table [3](#T3){ref-type="table"}**). Comprehensive *in vitro* evidence supports the view that hENT1 activity is a key determinant of gemcitabine action. Overexpression of hENT1 enhances gemcitabine response in human pancreatic cancer, and cells lacking hENT1 expression are highly resistant to gemcitabine ([@B106]; [@B123], [@B124]). There is increasing evidence supporting the view that hENT1 is a predictive biomarker for the use of gemcitabine. Several studies have explored hENT1 expression in gemcitabine-treated solid tumors with various techniques (immunohistochemistry and qRT-PCR) and different treatment regimens trying to establish correlations with patient outcomes. The first studies demonstrated that hENT1 expression was prognostic in pancreatic cancer, but this research included both early (resected) and advanced disease, which were mostly treated with gemcitabine ([@B144]; [@B48]). Later, in patients with pancreatic cancer from a randomized phase III RTOG 9704 study, hENT1 expression was associated with increased OS and DFS in patients who received adjuvant gemcitabine chemotherapy, but not on those who received 5-fluorouracil ([@B37]). Moreover, in an analysis of 45 pancreatic cancer patients treated with postoperative adjuvant gemcitabine-based chemoradiation therapy, patients with high hENT1 expression had significantly longer DFS and OS than those with low hENT1 expression, and hENT1 expression was the only independent predictor for DFS and OS ([@B88]). Additional studies conducted up to now have provided encouraging but not yet convincing evidence of the use of this transporter as a suitable biomarker ([@B44]; [@B69]; [@B68]; [@B77]; [@B87]; [@B107]; [@B110]; [@B40]; [@B112]; [@B157]). This is probably because they have been mostly retrospective and have used non-randomized series of patients. On the contrary, only a few studies have provided no evidence supporting the use of hENT1 as a predictive biomarker for gemcitabine efficacy in a neoadjuvant gemcitabine-based chemoradiation setting ([@B68]) and in patients with advanced pancreatic cancer ([@B116]). However, none of the latter studies truly tested gemcitabine monotherapy in a defined group of patients. Recently, hENT1 expression was determined in a large unbiased group of patients that were given gemcitabine monotherapy (ESPAC3 trial), confirming its role as a predictive marker in gemcitabine-treated but not 5-fluorouracil-treated patients. This suggests that gemcitabine should not be used for patients with low tumor hENT1 expression ([@B54]). Nevertheless, it cannot be ruled out the fact that differences among studies should also be explained by the tools used in this type of analysis. In this sense, it has been recently stated that the two antibodies used to detect hENT1 are not equivalent ([@B146]).

###### 

hENT1 expression and clinical response.

  Transporter   Treatment                                 Assay     Cancer type     *n* =   Analysis                     Reference
  ------------- ----------------------------------------- --------- --------------- ------- ---------------------------- -----------
  hENT1         GE containing chemotherapy                IHQ       NSCLC           24      Response to therapy          [@B114]
  hENT1         GE                                        qRT-PCR   Bladder         12      Complete response            [@B93]
  hENT1         GE-CDDP                                   IHQ       Bladder         40      OS                           [@B91]
  hENT1         GE                                        IHQ       Biliary tract   31      TTP                          [@B138]
  hENT1         GE                                        IHQ       Biliary tract   26      OS and PFS                   [@B11]
  hENT1         GE                                        IHQ       Biliary tract   105     OS                           [@B72]
  hENT1         GE                                        IHQ       Biliary tract   28      OS                           [@B109]
  hENT1         GE monotherapy after operation            IHQ       Pancreas        434     OS                           [@B54]
  hENT1         GE                                        IHQ       Pancreas        169     Not a prediction biomarker   [@B116]
  hENT1         GE plus S-1 after operation               IHQ       Pancreas        109     OS and DFS                   [@B112]
  hENT1         GE-based chemoradiation after operation   IHQ       Pancreas        95      RFS                          [@B40]
  hENT1         GE-based chemotherapy                     IHQ       Pancreas        44      OS and DFS                   [@B157]
  hENT1         GE-based chemotherapy before operation    IHQ       Pancreas        55      OS                           [@B110]
  hENT1         GE-based chemotherapy after operation     IHQ       Pancreas        27      OS and DFS                   [@B107]
  hENT1         GE-based chemoradiation after operation   IHQ       Pancreas        222     OS                           [@B87]
  hENT1         GE plus S-1                               IHQ       Pancreas        86      OS and DFS                   [@B77]
  hENT1         GE-based chemotherapy after operation     qRT-PCR   Pancreas        40      OS                           [@B44]
  hENT1         GE-based chemoradiation after operation   IHQ       Pancreas        45      OS and DFS                   [@B88]
  hENT1         GE-based chemoradiation after operation   IHQ       Pancreas        91      OS and DFS                   [@B37]
  hENT1         GE adjuvant and palliative                qRT-PCR   Pancreas        81      OS                           [@B48]
  hENT1         GE palliative                             IHQ       Pancreas        21      OS                           [@B144]

Interestingly, correlations between intratumoral hENT1 expression and responsiveness to gemcitabine have also been reported to occur in other types of malignant tumors. Responses to gemcitabine-based chemotherapy were evident in patients with high hENT1 expression but not in patients without hENT1 expression in an analysis of 24 patients with non-small cell lung cancer ([@B114]). In bladder cancer, a first study with 12 cancer specimens showed a significant correlation between gemcitabine chemotherapy outcome and hENT1 expression ([@B93]). Later, the OS of patients treated with a gemcitabine-/cisplatin-based combination chemotherapy was significantly higher in patients with high hENT1 expression ([@B91]). In addition, a few studies in biliary cancer have shown an association between hENT1 expression, as determined by immunohistochemistry, and chemosensitivity to gemcitabine ([@B138]; [@B11]; [@B72]; [@B109]).

BIOMARKER OF PROGNOSIS
----------------------

Besides the role of NT proteins as biomarkers of drug susceptibility discussed above, NT expression by itself might be a biomarker of disease prognosis, although available data are controversial so far. This is due to the fact that almost all studies have included treated-patients. Indeed, hENT1 itself has been related to epithelial mesenchymal transition (EMT) probably independently of its role as a drug transporter ([@B58]; [@B82]). Thus, it is likely that these proteins can also serve as prognostic biomarkers. Although several studies analyzed the prognostic value of intratumoral hENT1 expression in patients who had not received gemcitabine chemotherapy, in many of them it is not possible to discriminate between a therapeutic predictive effect and a disease prognostic effect for hENT1 expression due to the patient cohort choice, often based on retrospective analysis. A retrospective analysis of 111 patients with resected gastric cancer who had not received gemcitabine-based chemotherapy revealed that patients with high hENT1 expression had a shorter OS or DFS than those with low hENT1 expression ([@B139]). Similar results were also reported in 41 patients with ampullary cancer ([@B137]). In ampullary carcinoma, hENT1 expression and proliferation index were found to be dependent on the histological subtypes, suggesting a key role of hENT1 in tumor growth ([@B125]). In biliary tract malignancies, high expression of hENT1 was correlated with improved OS, although the study was performed in 63 patients including intrahepatic, hilar, or distal cholangiocarcinoma and gallbladder carcinoma and a small group of patients within this cohort had been treated with nucleoside analogs ([@B39]). In addition, in a study with 84 pancreatic cancer patients, low expression of hENT1 was associated with shorter OS and progression free survival (PFS) independently of gemcitabine treatment ([@B69]). In an attempt to clarify this point, [@B54] examined the expression of hENT1 combining the observation arms from the ESPAC1 and ESPAC3 trials that were specifically randomized to no adjuvant treatment. Although the resultant number of cases investigated was small, there was no evidence to support hENT1 expression levels *per se* as indicative of OS ([@B54]). However, further studies on a larger number of patients with various cancers are needed to clarify the role of hENT1 as a prognostic biomarker. Furthermore, the analysis of NTs expression in nearly 300 gynecologic tumors (ovary, endometrium, and uterine cervix carcinomas) showed loss of hCNT1 in a much higher number of cases than hENT1 and hENT2 and, this loss highly correlated with poor prognosis histotypes ([@B36]). In breast cancer, hCNT1 alone exhibited prognostic value for DFS and risk of relapse ([@B49]).

A major bottleneck in the interpretation of the available data is the fact that almost all the studies addressed to determine the role of NTs as prognosis biomarkers in cancer analyzed different grades of the disease without a direct comparison with healthy tissue.

GENETIC HETEROGENEITY AS BIOMARKER
----------------------------------

Compared to other drug transporter encoding-genes, neither SLC28 nor SLC29 genes appear to be highly polymorphic in humans ([@B34]). On the contrary, hOCTs are highly polymorphic proteins, with some variants showing high allelic frequency in humans, being relevant to the pharmacokinetics of selected drugs such as metformin ([@B34]).

Pharmacogenetic studies of hENT1 have not clearly identified yet any clinical relevance of the inter-individual sequence variations in the hENT1 encoding gene (SLC29A1). Although single nucleotide polymorphisms (SNPs) in hENT1 have been identified, none have demonstrated functional consequences in terms of drug uptake or accumulation ([@B117]; [@B70]; [@B111]). However, a recent study of 154 patients treated with neoadjuvant gemcitabine suggested that a combined assessment of six SNPs, including the hENT1 T-549C allele and hENT1 C913T allele, did correlate to OS ([@B115]). While multiple alternatively spliced variants encoding hENT1 have been identified, they have not been shown to have clinical relevance so far. As for hENT1, hENT2 also shows different spliced variants, some of them likely to be translated into proteins, although their physiological relevance is also unknown ([@B85]). Regarding the other members of the SLC29 gene family, as mentioned above, hENT3 has been directly implicated in the pathogenesis of human disease. Loss-of-function mutations in the hENT3 encoding gene have been associated with familial Rosai-Dorfman disease, Faisalabad histiocytosis, H syndrome, and PHID ([@B98]; [@B20]; [@B67]; [@B105]; [@B143]; [@B2]). Despite some controversy about the intracellular location of this transporter protein, it has recently been shown that ENT3 null mice develop defects in the lysosomal system, causing ineffective apoptotic cell clearance and increased M-CSF signaling which contribute to increase macrophage number and histiocytosis ([@B60]).

Although hCNTs do not appear to be particularly variable at the gene level, some polymorphisms have been identified and supposed to have clinical relevance ([@B34]). Functional complexity of selected polymorphic variants can be paradigmatic, as for the Spanish hCNT3 variant (hCNT3 Cys602Arg) which shows variable affinities for hCNT3 substrates, apparent loss of interaction with one of the two Na^+^ ions being translocated along with the drug, and lipid raft missorting of the mutated variant, thereby dramatically affecting its biological function ([@B32], [@B33]; [@B13]; [@B15]). Genetic variability of the SLC28 genes has recently been addressed also in the context of ribavirin-based therapies in patients infected with the HCV. The analysis of SLC28A2, SLC28A3, SLC29A1, and SLC29A2 variants in a cohort of 169 patients cronically infected with HCV did not show any significant correlation with response to treatment. However, the SLC28A3 haplotype rs10868138G/rs56350726T was associated with protection against ribavirin-induced hemolytic anemia ([@B27]), a finding which may be difficult to interpret as long as hENT1 is the major NT in erythrocytes. Moreover, the SLC28A3 rs56350726T variant has also been associated with SVR in a cohort of 216 patients. Some of these polymorphisms might probably affect ribavirin pharmacokinetics, as for the SLC28A2 rs11854484 variant, which was linked in the same study to high plasma ribavirin levels during combined PegIFN-α/ribavirin treatment ([@B130]). The same SLC28A2 variant was previously significantly associated with SVR ([@B22]). Interestingly, the SCL28A2 gene product, hCNT2, has recently been shown to be a ribavirin transporter that is regulated by INF-α ([@B126]). Notwithstanding, considering the impact of ribavirin transporters in the clinical outcome there are limited data relative to the expression of these transporters and their polymorphisms.

NTs AS DRUG TARGETS
===================

Nucleotides and nucleosides can be supplied by either salvage or by de novo synthesis from smaller precursors. NTs perform a crucial role in maintaining nucleoside homeostasis under physiological conditions through provision of nucleosides and nucleobases derived from the diet or produced by tissues such as liver. In this sense, as mentioned above NTs show less functional diversity than other transporter proteins and it has been suggested, as for hCNT3 as a paradigm within this family, that any change can critically compromise "fitness" in humans ([@B4]). This would be consistent with low evolutionary-related heterogeneity and, at least up to now, no genetic-based diseases associated with this gene family.

MORE THAN TRANSPORTERS
----------------------

For years the study of these membrane proteins in the context of anticancer therapy has focused on the role these proteins might play in drug efficacy and safety. Notwithstanding, cancer represents an important pathophysiological condition that requires abnormally high levels of nucleoside influx to support higher amounts of DNA synthesis associated with the disease. Most cells express several NT-encoding genes, thereby anticipating some sort of apparent functional redundancy when analyzing transporter profiles, particularly considering that transporters often show overlapping or even identical selectivity profiles. Indeed, hCNT expression is commonly associated with fully differentiated cell types ([@B101]; [@B121]; [@B15]; [@B104]) and oncogenesis often results in hCNT down-regulation, particularly in hCNT1 ([@B36]; [@B163]; [@B80]; [@B9]; [@B89]; [@B97]; **Table [4](#T4){ref-type="table"}**). However, the evidence of hCNT1 loss during oncogenesis needs further investigation, because almost all the studies performed so far focused exclusively on hCNT1-related mRNA levels. We have recently demonstrated that restoration of hCNT1 function in pancreatic adenocarcinoma cell lines is able to induce cell cycle arrest, increase cell death by a non-apoptotic mechanism, trigger changes in some intracellular signaling cascades and inhibit cell migration ([@B124]). More importantly, all these events can also be induced when expressing a mutated hCNT1 protein that localizes to the plasma membrane but lacks the ability to translocate substrates. Remarkably, hCNT1 protein restoration can also inhibit tumor growth in a mouse model of pancreatic adenocarcinoma ([@B124]). These observations would argue in favor of hCNT1 being a transceptor protein. This new concept within the field comes from seminal studies both in mammalian cells and yeast: a transporter that in a substrate translocation-dependent or -independent manner is able to modulate cell functions, behaving as a signaling-inducer molecule or a receptor itself. Several examples of SLC membrane transporters with these additional regulatory roles have recently been reported in the literature ([@B78]; [@B21]; [@B124]; [@B148]).

###### 

NTs expression in tumor tissue.

  Transporter   Tumor             Assay         *n* =   Expression   Compared vs. healthy tissue   Reference
  ------------- ----------------- ------------- ------- ------------ ----------------------------- -----------
  hCNT1         Breast            IHQ                   Decreased    Yes                           [@B80]
  hCNT1         Pancreas          qRT-PCR, WB   5       Decreased    Yes                           [@B9]
  hCNT1         Ovary             IHQ           90      Decreased    No                            [@B36]
  hCNT1         Endometrium       IHQ           79      Decreased    No                            [@B36]
  hCNT1         Uterine cervix    IHQ           118     Decreased    No                            [@B36]
  hCNT1         Pancreas          qRT-PCR       32      Decreased    Yes                           [@B97]
  hCNT1         Hepatocarcinoma   qRT-PCR       10      Decreased    Yes                           [@B163]
  hCNT1         Bladder           qRT-PCR       12      Decreased    No                            [@B93]
  hCNT3         Pancreas          qRT-PCR       32      Decreased    Yes                           [@B97]
  hENT1         Breast            IHQ                   Decreased    Yes                           [@B80]
  hENT1         Pancreas          qRT-PCR       32      Decreased    Yes                           [@B97]

The possibility of hCNT proteins behaving as putative transceptors might also apply to the other two members of the *SLC28* gene family, hCNT2 and hCNT3. In contrast to hCNT1, both are high affinity adenosine transporters likely to modulate extracellular adenosine levels and, consequently, purinergic signaling. CNT2 was shown to be under the control of A1 adenosine receptors in hepatocytes by a mechanism which is dependent upon ATP-sensitive potassium channels and glucose availability ([@B29]; [@B92]). A similar receptor-transporter crosstalk has recently been reported for CNT2 in neurons ([@B92]), being CNT2 expression down-regulated in the rat brain by sleep deprivation and experimental ictus ([@B57]; [@B92]). Moreover, adenosine taken up by CNT2 is responsible for AMP-dependent protein kinase (AMPK) activation in epithelial and neuronal models ([@B3]; [@B92]). As for CNT1, CNT2 expression appears to be characteristic of differentiated hepatocytes ([@B26], [@B25]; [@B28]) being regulated by glucocorticoids and hepatocyte-specific transcription factors ([@B151]; [@B38]). On the other hand CNT3, which is not expressed in normal hepatocytes but shows broad expression in other epithelial tissues, such as colon and biliary epithelia, also appears to be a major player in regulating extracellular adenosine levels. In fact, CNT3 is under purinergic control via A2a adenosine receptors in cholangiocytes, thereby contributing to end up the initially driven purinergic control of bile flow started by ATP secretion into the bile ([@B50]). This evidence suggest that selected NT proteins can indeed be part of the purinome, the molecular network of nucleoside and nucleotide receptors (P1 and P2), enzymes, and transporters responsible for purinergic regulation of cell functions ([@B154]). As long as some of the membrane proteins within the purinome, and other drug transporters as well, might eventually exert physiological effects other than the mere uptake or release of drugs, it can be anticipated that clinical implications of the changes in the transportome associated with the progression of disease will have to be evaluated from different perspectives and are likely to become suitable biomarkers and even drug targets.

FUTURE PERSPECTIVES
===================

Academic research focused on human NT proteins has established so far the basis for anticipating a probable role of these membrane proteins as biomarkers of diagnosis and prognosis. One major bottleneck in translational research within this field is the lack of suitable tools. Highly reliable antibodies are needed for both immunohistochemistry and flow cytometry, although quantitative proteomics can also prove to be suitable for biomarker analysis. This would enable more comprehensive, well structured, prospective clinical studies. The determination of NT protein expression during oncogenesis and the likely relationship between changes in the NT profile and stages of tumor progression would make these biomarkers very robust, although this progress is highly dependent upon the availability of well characterized clinical specimens. A major breakthrough within the field might come from the elucidation of NT interactomics, aiming at linking NTs with other cellular events that would help in the understanding of the biological basis of their use as biomarkers.
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CLL

:   chronic lymphocytic leukemia

CMV

:   cytomegalovirus

CNT

:   concentrative nucleoside transporter

DFS

:   disease free survival

ENT

:   equilibrative nucleoside transporter

HBV

:   hepatitis B virus

HCV

:   hepatitis C virus

HIV

:   human immunodeficiency virus

HSV

:   herpes simplex virus

NBTI

:   nitrobenzylthioinosine

NT

:   nucleoside transporter

OAT

:   organic anion transporter

OCT

:   organic cation transporter

OCTN

:   organic cation/carnitine transporters

OS

:   overall survival

PEPT

:   peptide transporter

SLC

:   solute carrier transporter

SVR

:   sustained virological response.
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